| 臺大學術典藏 |
2020-02-06T05:21:56Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Lai M.-S.;Yang J.C.H.;Cheng A.-L.;WEN-FANG CHENG;Hsu C.;Shao Y.-Y.;Yang Y.-Y.;Lai C.-L.;Shau W.-Y.;Kuo R.;Lin Z.-Z.;Kuo H.-Y.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; WEN-FANG CHENG; Cheng A.-L.; Yang J.C.H.; Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; WEN-FANG CHENG; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2020-01-22T04:47:49Z |
Integrated stable isotope labeling by amino acids in cell culture (SILAC) and isobaric tags for relative and absolute quantitation (iTRAQ) quantitative proteomic analysis identifies galectin-1 as a potential biomarker for predicting sorafenib resistance in liver cancer
|
Yeh C.-C.;Hsu C.-H.;Shao Y.-Y.;Ho W.-C.;Tsai M.-H.;Feng W.-C.;Lu-Ping Chow; Yeh C.-C.; Hsu C.-H.; Shao Y.-Y.; Ho W.-C.; Tsai M.-H.; Feng W.-C.; LU-PING CHOW |
| 臺大學術典藏 |
2020 |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; CHIUN HSU |
| 國立成功大學 |
2020 |
Satisfaction with pain management and impact of pain on quality of life in cancer patients
|
Lin, J.;Hsieh, R.-K.;Chen, J.-S.;Lee, K.-D.;Rau, K.-M.;Shao, Y.-Y.;Sung, Y.-C.;Yeh, S.-P.;Chang, Chang C.-S.;Liu, T.-C.;Wu, M.-F.;Lee, M.-Y.;Yu, M.-S.;Yen, C.-J.;Lai, P.-Y.;Hwang, W.-L.;Chiou, T.-J. |
| 臺大學術典藏 |
2019 |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Lu L.-C.; Shen Y.-C.; Chiun Hsu; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.; Liu T.-H.; Shao Y.-Y. |
| 臺大學術典藏 |
2019 |
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
|
Chang C.-J.; Lee Y.-H.; Lu L.-C.;Lee Y.-H.;Chang C.-J.;Shun C.-T.;Fang C.-Y.;Shao Y.-Y.;Liu T.-H.;Cheng A.-L.;Chih-Hung Hsu; Lu L.-C.; Shun C.-T.; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; Cheng A.-L.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2019 |
Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
|
Guo J.-C; Chia-Chi Lin; Lin C.-Y; Hsieh M.-S; Kuo H.-Y; Lien M.-Y; Shao Y.-Y; Huang T.-C; Hsu C.-H. |
| 臺大學術典藏 |
2019 |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; CHIUN HSU; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 國立成功大學 |
2019 |
A nationwide survey of adherence to analgesic drugs among cancer patients in Taiwan: prevalence, determinants, and impact on quality of life
|
Chou, W.-C.;Chen, J.-S.;Hung, C.-Y.;Lu, C.-H.;Shao, Y.-Y.;Chiou, T.-J.;Sung, Y.-C.;Rau, K.-M.;Yen, C.-J.;Yeh, S.-P.;Liu, T.-C.;Wu, M.-F.;Lee, M.-Y.;Yu, M.-S.;Hwang, W.-L.;Lai, P.-Y.;Chang, Chang C.-S.;Hsieh, R.-K. |
| 國立成功大學 |
2019 |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu, Lu L.-C.;Hsu, C.;Shao, Y.-Y.;Chao, Y.;Yen, C.-J.;Shih, I.-L.;Hung, Y.-P.;Chang, Chang C.-J.;Shen, Y.-C.;Guo, J.-C.;Liu, T.-H.;Hsu, C.-H.;Cheng, A.-L. |
